Contents

1 Introduction **1**

1.1 Challenges in targeted cancer therapy 3
1.2 Modelling in systems biology 5
1.3 Perturbation data-based models 7
1.3.1 Dynamic network modelling 8
1.3.2 Modular Response Analysis (MRA) 9
1.4 Obstacles for field application of MRA 12
1.5 Objectives 13

2 Reverse engineering of genetic networks **15**

2.1 Introduction 15
2.2 Statistical extension of MRA 18
2.2.1 Maximum likelihood extension 18
2.2.2 Greedy hill-climbing model selection 19
2.3 Parameter benchmark on *in silico* networks 21
2.3.1 Artificial gene regulatory network generation 21
2.3.2 Parameter benchmark of refined MRA approach 23
2.4 Comparison to alternative methodologies 30
2.4.1 Established steady state prediction methods 31
2.4.2 Performance on default settings with different interaction types 31
2.4.3 Detailed method assessment on transcription factor networks 33
2.4.4 External benchmark: DREAM 4 network challenge 35
2.5 Discussion 37
2.5.1 Top-down analysis of an oncogenic KRAS-controlled transcriptional network 39
2.5.2 Future directives to advance in genetic network research . . 41
2.5.3 Improvements for further use of extended MRA 43

3 Modelling EGFR signalling in a colon cancer panel 47
3.1 Introduction . . . 47
3.1.1 Study design . . . 49
3.2 Adjusting MRA to model signalling data . . . 52
3.2.1 Modelling incomplete data . . . 52
3.2.2 Integration of different perturbation types . . . 54
3.2.3 Removing non-identifiable parameters . . . 56
3.2.4 Parameter estimation strategy . . . 60
3.3 Modelling results . . . 61
3.3.1 Model fit suggests extension of the original network model . 62
3.3.2 Robustness assertion of model parameters . . . 66
3.3.3 Model fit uncovers differences in network structure . . . 70
3.3.4 Quantitative differences between signalling networks . . . 71
3.4 Model assisted study of the ERK-AKT crosstalk . . . 73
3.4.1 Verification and characterisation of the crosstalk between ERK and AKT . . . 73
3.4.2 Prediction of potentially effective double inhibitions . . . 75
3.4.3 Combined inhibition of EGFR and ERK prevents growth in various tumour cells . . . 77
3.5 Discussion . . . 79
3.6 Concluding Remarks . . . 82

4 Conceptual modelling resolves role of TTP in HIF-1 regulation 85
4.1 Introduction . . . 85
4.1.1 Molecular function of HIF-1 . . . 86
4.1.2 Study of normoxic HIF-1 regulation reveals controversial observation . . . 87
4.2 Model-supported hypothesis testing . . . 89
4.2.1 MRA application scheme for hypothesis testing . . . 90
4.2.2 Model scenarios . . . 91
4.2.3 Experimental testing of model hypotheses . . . 95
4.3 Discussion . . . 97
4.3.1 Uses and limitations of MRA for theoretical modelling . . . 98

5 Conclusion 101
5.1 MRA extensions enabled modelling of biological networks . . . 101
5.2 Outlook I: Technical improvement plans . . . 103

5.3 Outlook II: Future applications of MRA in systems biology 105
5.3.1 Analysing signalling in cancer research 106
5.4 Closing remark 109

Appendix 111

A Appendix for chapter: Reverse engineering of genetic networks 113
A 1 Parametrisation of simulated genetic networks 113
A 2 Evaluation statistics 116
A 3 Complete parameter benchmark results of ML MS MRA 117
A 4 Alternative steady state prediction methods 120
A 5 Extended modelling results for DREAM 4 challenge 2 123
A 6 Assessment of two estimates of the global response matrix 125
A 6.1 Error propagation 126
A 6.2 Performance comparison on *in silico* networks 128

B Appendix for chapter: Modelling EGFR signalling in a colon cancer panel 129
B 1 Phosphorylation kinetics after stimulation 129
B 2 Error model for signalling data 130
B 3 Model reduction example 131

C Appendix for chapter: Conceptual modelling resolves role of TTP in HIF-1 regulation 133
C 1 MRA models to elucidate TTP-HIF-1α relationship 133

D Appendix for chapter: Conclusion 139
D 1 FDA approved targeted therapy drugs 139

E Abbreviations 142

Bibliography 145

Danksagungen 171